Merck & Company Inc (MRK)vsPrenetics Global Ltd (PRE)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
PRE
Prenetics Global Ltd
$16.71
-4.02%
HEALTHCARE · Cap: $310.15M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 70266% more annual revenue ($65.01B vs $92.39M). MRK leads profitability with a 28.1% profit margin vs -63.1%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
PRE
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+17.4%
Fair Value
$25.92
Current Price
$16.71
$9.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 248.6% year-over-year
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -31.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : PRE
The strongest argument for PRE centers on Revenue Growth, Price/Book. Revenue growth of 248.6% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : PRE
The primary concerns for PRE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while PRE is a hypergrowth play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.28 — expect wider price swings.
PRE is growing revenue faster at 248.6% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 35/100), backed by strong 28.1% margins. PRE offers better value entry with a 17.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Prenetics Global Ltd
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Prenetics Global Ltd (PRE) is a premier health technology innovator focused on delivering advanced genetic and diagnostic testing solutions that empower consumers and healthcare professionals with critical health insights. With a diverse portfolio of state-of-the-art testing services and integrated digital health offerings, the company has seen significant international growth, fueled by strategic partnerships and a strong commitment to ongoing research and development. As a frontrunner in the personalized medicine space, Prenetics is ideally positioned to capitalize on the increasing demand for accessible and actionable health information, representing a compelling investment opportunity in the dynamic healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?